ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "infection and rheumatoid arthritis (RA)"

  • Abstract Number: 223 • 2018 ACR/ARHP Annual Meeting

    The Effect of Concomitant Diabetes on RA-Related Outcomes: Results from the Acr’s RISE Registry

    Huifeng Yun1, Fenglong Xie1, Lang Chen1, Shuo Yang1, Leticia Ferri2, Evo Alemao2, Tammy Curtice2 and Jeffrey R. Curtis1, 1University of Alabama at Birmingham, Birmingham, AL, 2Bristol-Myers Squibb, Princeton, NJ

    Background/Purpose: The impact of concomitant comorbidities on RA outcomes is of high interest, and some evidence suggests that patients (pts) with RA and diabetes may…
  • Abstract Number: 519 • 2018 ACR/ARHP Annual Meeting

    Marginal Structure Modeling of Association between Disease Activity and Hospitalized Infection Among Patients in a Rheumatoid Arthritis Registry

    Huifeng Yun1, Lang Chen1, Jason Roy2, Jeffrey D. Greenberg3 and Jeffrey R. Curtis1, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Pennsylvania, Philadelphia, PA, 3Hopital Hautepierre, Strasbourg, France

    Background/Purpose: Higher disease activity might be associated with a higher risk of developing infections among patients with rheumatoid arthritis (RA). Since no randomized trial has…
  • Abstract Number: 526 • 2018 ACR/ARHP Annual Meeting

    Bronchiectasis in RA Is a Crucial Risk Factor of Hospitalised Pneumonia Associated with Bdmards As Well As Interstitial Lung Disease

    Kyoko Honne1, Masashi Bando2, Makiko Mieno3, Masahiro Iwamoto4 and Seiji Minota5, 1Division of Rheumatology and Clinical Immunology, Jichi Medical University, Shimotsuke, Japan, 2division of pulmonary medicine, Department of medicine, Jichi Medical University, Shimotsuke, Japan, 3Center for Information, Jichi Medical University, Shimotsuke, Japan, 4Deivision of Rheumatology and Clinical Immunology, Jichi Medical University, Shimotsuke, Japan, 5Department of Internal Medicine, Division of Rheumatology/Clinical Immunology, Jichi Medical University, Shimotsuke, Japan

    Background/Purpose: Interstitial lung disease (ILD) is a risk factor of pneumonia in RA patients treated with biological DMARDs (bDMARDs) [1-4]. Bronchiectasis (BE) is a well-known…
  • Abstract Number: 1226 • 2018 ACR/ARHP Annual Meeting

    Effect of New Method for Pre-Administration Assessment of Intravenous Biologics on Infections in Patients with Rheumatoid Arthritis

    Sho Fukui1, Masei Suda2, Haruki Sawada3, Yukihiko Ikeda1, Mitsuru Watanabe4, Ayako Koido4, Rui Kawato5, Yasuhiro Suyama6, Hisanori Shimizu7, Haruyuki Yanaoka7, Ryo Rokutanda1, Hiromichi Tamaki1, Tokutaro Tsuda1, Ken-ichi Yamaguchi8, Mitsumasa Kishimoto1 and Masato Okada9, 1Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, 2Immuno-Rheumatology Center, St luke's International hospital, Tokyo, Japan, 3Immuno-rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, 4Immune-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, 5Immuno rheumatology center, St. Luke's International Hospital, Tokyo, Japan, 6Division of Rheumatology, JR Tokyo General Hospital, Tokyo, Japan, 7St. Luke's International Hospital, Tokyo, Japan, 8Allergy and Rheumatology, St. Luke's International Hospital, Tokyo, Japan, 9Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, Japan

    Background/Purpose: Biologics are widely used and effective treatments for rheumatoid arthritis (RA), but generally biologics are avoided when patients have active infections on the day…
  • Abstract Number: 2449 • 2018 ACR/ARHP Annual Meeting

    Prevalence and Risk Factors of Serious Infections in Rheumatoid Arthritis Patients Receiving the Biologic/Targeted Synthetic Dmards: A Propensity Score Analysis from the Hong Kong Biologics Registry

    Chi Chiu Mok, Ting Hung Wan and Lai Shan Fong, Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong

    Background/Purpose: To study the prevalence and risk factors for serious infections (SIs) in rheumatoid arthritis (RA) patients receiving the biologic / target synthetic (b/ts) DMARDs.…
  • Abstract Number: 2452 • 2018 ACR/ARHP Annual Meeting

    Incidence Rate and Clinical Characteristics of Herpes Zoster Infection in Korean Patients with Rheumatoid Arthritis Patients

    Su-Jin Moon1, Min Jung Kim2, Sun Kyung Lee2, So Hee Oh2, Hyoun-Ah Kim3 and Kichul Shin4, 1Bucheon St. Mary's Hospital, Division of rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Bucheon, Korea, Republic of (South), 2Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of (South), 3Department of Rheumatology, Ajou University School of Medicine, Suwon, Korea, Republic of (South), 4Kyungnam villa #102, Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of (South)

    Background/Purpose: Herpes zoster (HZ) infection is not uncommon in rheumatoid arthritis (RA) patients, especially in those treated with biologic or targeted synthetic (bts) disease-modifying antirheumatic…
  • Abstract Number: 2485 • 2018 ACR/ARHP Annual Meeting

    Comparison of Risk for Infection-Related Hospitalization and Associated Costs of Biologic Experienced Rheumatoid Arthritis Patients Treated with Abatacept Versus Other Targeted Disease Modifying Antirheumatic Drugs

    Damemarie Paul1, Laura McDonald1, Alexander Marshall2, Tammy Curtice3, Melissa Lingohr-Smith4, Brandy Menges4 and Jay Lin4, 1Bristol-Myers Squibb, Lawrenceville, NJ, 2HEOR, Bristol-Myers Squibb, Lawrenceville, NJ, 3Bristol-Myers Squibb, Princeton, NJ, 4Novosys Health, Green Brook, NJ

    Background/Purpose: Abatacept is a targeted disease-modifying antirheumatic drug (tDMARD) that has demonstrated a lower risk for infection in comparison with other tDMARDs among rheumatoid arthritis…
  • Abstract Number: 134 • 2017 ACR/ARHP Annual Meeting

    Baseline Characteristics and Rates of Hospitalized Infections in Patients with Rheumatoid Arthritis Treated with Non-TNF Inhibitors in Denmark and Sweden

    Kathrine Lederballe Grøn1, Elizabeth V. Arkema2, Bente Glintborg1, Johan Askling3 and Merete Lund Hetland4, 1The DANBIO registry and the Danish Departments of Rheumatology, Copenhagen, Denmark, 2Clinical Epidemiology Unit, Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, 3Unit of Clinical Epidemiology, Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, 4The DANBIO registry and the Danish Departments of Rheumatology, Glostrup, Denmark

    Background/Purpose: Hospitalized infections during treatment with biologic disease modifying drugs (bDMARDs) in rheumatoid arthritis (RA) are a concern. This have mainly been studied in patients…
  • Abstract Number: 528 • 2017 ACR/ARHP Annual Meeting

    Impact of Comorbidities on the Occurrence of Infections in Rheumatoid Arthritis Treated By Biologic Agents

    Christopher Banse1, Nicolas Chrin2, Pascal Rottenberg3, Sophie Pouplin4, thierry Lequerre5 and Olivier Vittecoq3, 1Rheumatology, Rouen University Hospital, Rouen, France, 2Department of Biostatistics, Rouen University Hospital, 76031 Rouen, France, ROUEN, France, 3INSERM U905 & Normandy University, Institute for Research and Innovation in Biomedicine, Rouen, France, 4Rheumatology Department & Inserm 905, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, 5Rheumatology Department, Rouen University Hospital, University of Rouen, 76031 Rouen, France., ROUEN, France

    Background/Purpose: to investigate the potential relationship between the number of comorbidities at initiation of biotherapy and the occurrence of a severe infection or recurrent infections…
  • Abstract Number: 813 • 2017 ACR/ARHP Annual Meeting

    Incidence of Herpes Zoster in Patients with Polymyalgia Rheumatica: A Population-Based Cohort Study

    Shafay Raheel1, Cynthia S. Crowson2 and Eric L. Matteson3, 1Rheumatology, Mayo Clinic, Rochester, MN, 2Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, 3Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN

    Background/Purpose: To determine the incidence, time trends and, severity of herpes zoster in a population-based incidence cohort of patients with polymyalgia rheumatic (PMR) compared to…
  • Abstract Number: 842 • 2017 ACR/ARHP Annual Meeting

    Risk of Serious Infection in Patients with Rheumatoid Arthritis Treated with Biologic Vs. Non-Biologic Dmards

    Gulsen Ozen1, Sofia Pedro2, Bryant R. England3, Bella Mehta4, Frederick Wolfe2 and Kaleb Michaud1, 1Rheumatology, University of Nebraska Medical Center, Omaha, NE, 2National Data Bank for Rheumatic Diseases, Wichita, KS, 3Division of Rheumatology & Immunology, Department of Internal Medicine, Nebraska-Western IA VA Health Care System & University of Nebraska Medical Center, Omaha, NE, 4Rheumatology, Hospital for Special Surgery/Weill Cornell Medical College, New York, NY

    Background/Purpose: Serious infections (SIs) are a major concern in RA patients, significantly contributing to increased mortality. We examined the SI risk associated with bDMARDs compared…
  • Abstract Number: 2391 • 2017 ACR/ARHP Annual Meeting

    Incidence of Infections in Early Arthritis

    Meriem Kerbachi1, Louis Bessette2, Cristiano S. Moura3, Sasha Bernatsky4, Orit Schieir5, Susan J. Bartlett6, Carol A Hitchon7, Janet E. Pope8, Gilles Boire9, Boulos Haraoui10, Edward C. Keystone11, Diane Tin12, Carter Thorne13 and Vivian P. Bykerk14, 1McGill University, Montreal, QC, Canada, 2Centre d'ostéoporose et de rhumatologie de Québec (CORQ), Québec, QC, Canada, 31Division of Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, 4Divisions of Rheumatology and Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 5McGill University, Montreal, ON, Canada, 6Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, 7University of Manitoba, Winnipeg, MB, Canada, 8Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada, 9Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, 10Institut de Rhumatologie de Montréal, Montreal, QC, Canada, 11Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada, 12The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, 13University of Toronto, Newmarket, ON, Canada, 142-005, Mt Sinai Hospital, Toronto, ON, Canada

    Background/Purpose: Few studies have focused on analyzing infection risk in recent-onset rheumatoid arthritis (RA).The main objective of this study was to estimate the incidence of…
  • Abstract Number: 2001 • 2016 ACR/ARHP Annual Meeting

    Perioperative Use of Synthetic Disease-Modifying Anti-Rheumatic Drugs or Tumor Necrosis Factor α Inhibitors Does Not Associate with Increased Rates of Post-Operative Infections

    Hsin-Hsuan Juo1,2, Anders Peck3,4, Nancy Gove5 and Bernard Ng1,2, 1Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA, 2Rheumatology, VA Puget Sound Healthcare System, Seattle, WA, 3Medicine / Rheumatology, University of Washington, Seattle, WA, 4The Seattle Arthritis Clinic, Seattle, WA, 5Biostatistics, Seattle Children's Research Institute, Seattle, WA

    Background/Purpose: The aim of the study is to assess whether the risk of post-operative infectious complications in rheumatoid arthritis (RA) patients undergoing surgical procedures is…
  • Abstract Number: 2053 • 2016 ACR/ARHP Annual Meeting

    Prosthetic Joint Infection with Staphylococcus Aureus: Recurrence after Surgical Treatment in U.S. Veterans with and without Rheumatoid Arthritis

    Namrata Singh1, Rajeshwari Nair2, Michihiko Goto3, Elizabeth Field4,5, Petar Lenert6, Ryan Carnahan7, Marin Schweizer2 and Eli Perencevich2, 1Internal Medicine, University of Iowa Hospitals and Clinics and Iowa City VA, Iowa City, IA, 2Internal Medicine, Iowa City VA, Iowa City, IA, 3Iowa city VA and UIHC, Iowa City, IA, 410e-01 Building 1 Vamc, University of Iowa, Iowa City, IA, 5Iowa City VA, Iowa City, IA, 6333 MRC Dept of Internal Med, University of Iowa, Iowa City, IA, 7Epidemiology, College of public health, UI, Iowa City, IA

    Background/Purpose:  Studies have shown rheumatoid arthritis (RA) to be a risk factor for development of prosthetic joint infections (PJI) and for worse outcome from PJI…
  • Abstract Number: 120 • 2016 ACR/ARHP Annual Meeting

    Reproductive Tract Infections (RTI) in Indian (Asian) Women of Child Bearing Age Suffering from RA:I Don’t Ask Them, They Don’t Tell Me

    Anuradha Venugopalan1, Jaleh Naderi2, Renu Relwani3 and Arvind Chopra4, 1Rheumatology, Microbiologist, Pune, India, 2Rheumatology, PhD Student, Urrmia, Iran, 3Rheumatology, Gynaecologist, Pune, India, 4Center for Rheumatic Diseases, Director and Chief Rheumatologist, Pune, India

    Background/Purpose: Several factors including disease process and drug therapy allegedly predispose to infections in RA. Socioeconomic constraints on our setting impose unique impediments. RTI are…
  • 1
  • 2
  • 3
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology